Reimbursement In Brief
This article was originally published in The Gray Sheet
CMS opens national coverage analysis for PET tracers to diagnose dementia. HHS Office of Inspector General reports on prosthetics and orthotics payments. More reimbursement news.
You may also be interested in...
Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.
Its spring 2013 Semiannual Report to Congress says the Office of Inspector General expects recoveries of about $3.8 billion from audits and investigations undertaken in the first half of fiscal year 2013, among other findings.
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.